183 related articles for article (PubMed ID: 16810619)
21. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
22. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
23. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
24. Essential Thrombocythemia: The Dermatologic Point of View.
Cozzani E; Iurlo A; Merlo G; Cattaneo D; Burlando M; Pierri I; Gugliotta L; Parodi A
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):739-47. PubMed ID: 26432058
[TBL] [Abstract][Full Text] [Related]
25. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
26. Essential thrombocythaemia in children: is a treatment needed?
Randi ML; Putti MC
Expert Opin Pharmacother; 2004 May; 5(5):1009-14. PubMed ID: 15155103
[TBL] [Abstract][Full Text] [Related]
27. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
Santoro C; Sperduti I; Latagliata R; Baldacci E; Anaclerico B; Avvisati G; Breccia M; Buccisano F; Cedrone M; Cimino G; De Gregoris C; De Muro M; Di Veroli A; Leonetti Crescenzi S; Montanaro M; Montefusco E; Porrini R; Rago A; Spadea A; Spirito F; Villivà N; Andriani A; Alimena G; Mazzucconi MG
Cancer Med; 2017 Jun; 6(6):1233-1239. PubMed ID: 28544749
[TBL] [Abstract][Full Text] [Related]
28. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
Barbui T; Finazzi G
Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
[TBL] [Abstract][Full Text] [Related]
29. Management of patients with essential thrombocythemia: current concepts and perspectives.
Briere J; Guilmin F
Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
[TBL] [Abstract][Full Text] [Related]
30. Essential thrombocythaemia treatment options: addressing patient-specific needs.
Birgegård G
Eur J Haematol Suppl; 2007 Oct; (68):27-31. PubMed ID: 17727563
[No Abstract] [Full Text] [Related]
31. Essential thrombocythemia.
Finazzi G; Harrison C
Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
[TBL] [Abstract][Full Text] [Related]
32. Essential thrombocythemia: scientific advances and current practice.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
[TBL] [Abstract][Full Text] [Related]
33. Essential thrombocythemia (ET): moving from palliation to cure.
Tsimberidou AM; Giles FJ
Hematology; 2002 Dec; 7(6):315-23. PubMed ID: 12475736
[TBL] [Abstract][Full Text] [Related]
34. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
van Genderen PJ; Leenknegt H; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):385-9. PubMed ID: 9263356
[TBL] [Abstract][Full Text] [Related]
35. Thrombocytosis.
Schafer AI
N Engl J Med; 2004 Mar; 350(12):1211-9. PubMed ID: 15028825
[No Abstract] [Full Text] [Related]
36. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
37. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
38. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Andersson BS
Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
[No Abstract] [Full Text] [Related]
39. Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review.
Sobas MA; Pérez Encinas MM; Rabuñal Martinez MJ; Quinteiro García C; Bello López JL
Acta Haematol; 2009; 122(4):221-2. PubMed ID: 19887779
[No Abstract] [Full Text] [Related]
40. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
Antelo ML; de Las Heras N; Gonzalez Porras JR; Kerguelen A; Raya JM
Expert Rev Hematol; 2015 Dec; 8(6):819-35. PubMed ID: 26368319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
